BioSphere Medical, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioSphere Medical, Inc.
Dr Reddy’s Q1 Talking Points: Solid US Gains, Mark Cuban Cost Plus Drug Co, China
A sharp upswing in the US business, an alliance with Mark Cuban’s venture and a buoyant outlook in markets like China augur well for Dr Reddy’s. Can the company sustain momentum for the rest of year?
Dr Reddy’s Q1 Talking Points: Solid US Gains, Mark Cuban Cost Plus Drug Co, China
A sharp upswing in the US business, an alliance with Mark Cuban’s venture and a buoyant outlook in markets like China augur well for Dr Reddy’s. Can the company sustain momentum for the rest of year?
Myovant Spurns Sumitovant Offer, Remains Open To Higher-Value Deal
Sumitovant offered $22.75 per share in cash, valuing Myovant at $2.4bn total, to acquire what it does not hold as a result of its 2019 agreement to buy majority shares of five Roivant companies.
Recordati Expands Into Rare Cancer Space With EUSA Pharma Buy
The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice